Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) shares fell 5.9% during trading on Tuesday . The stock traded as low as $2.69 and last traded at $2.64. 965,092 shares changed hands during trading, a decline of 68% from the average session volume of 3,033,330 shares. The stock had previously closed at $2.80.
Analyst Ratings Changes
Several equities research analysts recently commented on TSHA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Chardan Capital boosted their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Finally, Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has an average rating of "Buy" and a consensus target price of $7.57.
Get Our Latest Report on TSHA
Taysha Gene Therapies Stock Up 2.3%
The company's 50 day moving average price is $2.10 and its two-hundred day moving average price is $1.93. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a market cap of $573.15 million, a PE ratio of 4.24 and a beta of 1.04.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.30 million for the quarter, compared to analysts' expectations of $1.48 million. During the same period last year, the firm earned ($0.10) EPS. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.
Insider Transactions at Taysha Gene Therapies
In related news, major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the purchase, the insider now owns 2,841,704 shares in the company, valued at $7,814,686. The trade was a 35.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.70% of the company's stock.
Hedge Funds Weigh In On Taysha Gene Therapies
A number of hedge funds have recently modified their holdings of TSHA. Ground Swell Capital LLC bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $25,000. Cibc World Markets Corp purchased a new stake in Taysha Gene Therapies in the 4th quarter worth $28,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth $31,000. Hsbc Holdings PLC raised its holdings in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after acquiring an additional 8,076 shares during the period. Finally, AXQ Capital LP purchased a new position in shares of Taysha Gene Therapies in the fourth quarter valued at about $39,000. 77.70% of the stock is currently owned by institutional investors.
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Stories
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
